ANIP
ANI PHARMACEUTICALS INC
+1.08 (+1.47%)74.67USD138K成交股數1.8B市值16.2本益比(近四季)1.9股價營收比+25.9%營收年增(近四季)2026-11-06下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 266M+35% | 237M+25% | 228M+54% | 211M+53% | 197M+43% | 191M+45% | 148M+27% | 138M+29% | 137M | 132M | 117M | 107M |
| 營業成本 | 100M | 93.6M | 93.4M | 74.6M | 73.0M | 80.3M | 63.1M | 57.7M | 49.2M | 48.1M | 42.3M | 37.7M |
| 毛利 | 166M+34% | 144M+30% | 134M+58% | 137M+70% | 124M+41% | 110M+32% | 85.3M+15% | 80.3M+16% | 88.3M | 83.7M | 74.3M | 69.1M |
| 毛利率 | 62.4% | 60.6% | 59.0% | 64.7% | 62.9% | 57.9% | 57.5% | 58.2% | 64.2% | 63.5% | 63.7% | 64.7% |
| 研發費用 | 14.7M | 10.6M | 12.3M | 16.5M | 10.6M | 16.6M | 10.1M | 7.3M | 10.5M | 11.1M | 7.4M | 5.9M |
| 銷售管理費用 | 91.7M | 73.7M | 76.7M | 81.8M | 76.5M | 69.7M | 79.1M | 52.8M | 48.0M | 42.0M | 38.8M | 36.5M |
| 營業利益 | 40.5M+54% | 38.9M-988% | 36.2M-277% | 13.9M+169% | 26.2M+29% | −4.4M-124% | −20.5M-265% | 5.2M-48% | 20.3M | 17.9M | 12.4M | 9.9M |
| 營業利益率 | 15.2% | 16.4% | 15.9% | 6.6% | 13.3% | -2.3% | -13.8% | 3.7% | 14.8% | 13.6% | 10.6% | 9.3% |
| 稅後淨利 | 24.7M+58% | 29.5M-374% | 26.6M-210% | 8.5M-474% | 15.7M-14% | −10.8M-208% | −24.2M-487% | −2.3M-259% | 18.2M | 9.9M | 6.2M | 1.4M |
| 淨利率 | 9.3% | 12.4% | 11.7% | 4.0% | 8.0% | -5.6% | -16.3% | -1.7% | 13.2% | 7.5% | 5.4% | 1.3% |
| 稀釋 EPS | 1.05+52% | 1.28-384% | 1.13-189% | 0.36-357% | 0.69-16% | -0.45-200% | -1.27-538% | -0.14-333% | 0.82 | 0.45 | 0.29 | 0.06 |
| 稀釋股數 | 21.9M | 21.5M | 21.1M | 20.3M | 20.0M | 19.3M | 19.4M | 19.3M | 19.4M | 19.1M | 17.9M | 16.5M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 360M | 311M | 263M | 218M | 150M | 145M | 145M | 240M | 229M | 193M | 162M | 67.8M |
| 應收帳款 | 274M | 255M | 253M | 226M | 220M | 222M | 196M | 166M | 172M | 179M | 173M | 175M |
| 存貨 | 143M | 143M | 146M | 138M | 137M | 137M | 148M | 125M | 114M | 107M | 104M | 104M |
| 總資產 | 1.5B | 1.4B | 1.4B | 1.3B | 1.3B | 1.3B | 1.3B | 921M | 915M | 890M | 859M | 765M |
| 有息負債 | 280M | 286M | 298M | 301M | 305M | 309M | 313M | 284M | 285M | 285M | 285M | 285M |
| 總負債 | 897M | 860M | 902M | 881M | 849M | 856M | 857M | 440M | 438M | 435M | 425M | 426M |
| 股東權益 | 597M | 562M | 506M | 437M | 419M | 404M | 406M | 456M | 452M | 430M | 410M | 315M |
| 負債比 | 60.0% | 60.5% | 64.1% | 65.6% | 65.7% | 66.6% | 66.5% | 47.8% | 47.9% | 48.9% | 49.4% | 55.6% |
| 淨現金(現金 − 有息負債) | 80.1M | 25.2M | −35.1M | −83.7M | −155M | −164M | −168M | −44.3M | −56.0M | −92.0M | −124M | −218M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 58.4M | – | – | 35.0M+92% | – | – | – | 18.3M | – | – | 21.4M |
| 資本支出 | – | 6.1M | – | – | 2.5M | – | – | – | 4.6M | – | – | 2.3M |
| 自由現金流 | – | 52.3M | – | – | 32.5M+138% | – | – | – | 13.7M | – | – | 19.1M |
| 折舊攤銷 | 19.6M | 20.9M | 22.6M | 23.3M | 22.9M | 22.6M | 15.7M | 14.7M | 14.7M | 15.2M | 14.7M | 14.7M |
| 買回庫藏股 | – | 19.8M | – | – | 10.0M | – | – | – | 8.7M | – | – | 3.5M |
| 現金股利 | – | 0 | – | – | 406K | – | – | – | 406K | – | – | 406K |
| 自由現金流率 | – | 22.0% | – | – | 16.5% | – | – | – | 10.0% | – | – | 17.9% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 883M
| Rare Disease And Brands | 484M | 54.8% | +64.4% |
|---|---|---|---|
| Generics And Other | 399M | 45.2% | +24.8% |
地區2025 年度 · 883M
| 美國 | 852M | 96.5% | +40.9% |
|---|---|---|---|
| 美國以外 | 30.9M | 3.5% | +229.4% |
產品／服務2025 年度 · 523M
| Sales Of Cortrophin Gel | 348M | 66.5% | +75.6% |
|---|---|---|---|
| Sales Of ILUVIEN And YUTIQ | 74.9M | 14.3% | +137.6% |
| Sales Of Established Brands | 61.3M | 11.7% | -5.3% |
| Unapproved Products | 24.1M | 4.6% | +7.6% |
| Sales Of Royalties And Other Pharmaceutical Services | 15.3M | 2.9% | -19.6% |
| Total Sales Of Rare Disease And Brands 小計 | 484M | 92.5% | +64.4% |
| Total Sales Of Rare Disease Pharmaceutical Products 小計 | 423M | 80.8% | +84.1% |
| Total Sales Of Generics And Other 小計 | 399M | 76.3% | +24.8% |
| Sales Of Generic Pharmaceutical Products 小計 | 384M | 73.4% | +27.6% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 883M | +43.8% | 78.0M | 8.8% | 3.32 | 171M |
| FY2024 | 614M | +26.2% | −19.0M | -3.1% | -1.04 | 47.8M |
| FY2023 | 487M | +53.9% | 19.0M | 3.9% | 0.85 | 110M |
| FY2022 | 316M | +46.4% | −48.0M | -15.2% | -3.05 | −40.1M |
| FY2021 | 216M | +3.7% | −43.0M | -19.9% | -3.40 | 765K |
| FY2020 | 208M | +0.9% | −22.5M | -10.8% | -1.88 | 9.1M |
| FY2019 | 207M | +2.5% | 6.1M | 3.0% | 0.50 | 39.0M |
| FY2018 | 202M | – | 15.5M | 7.7% | 1.30 | 61.3M |